HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Altus

This article was originally published in The Tan Sheet

Executive Summary

Quaker Take Heart TV, print ads planned for western New York test marketing of Reducol-containing products, Novartis/Quaker joint venture says Aug. 2. Take Heart cereal available in two flavors at $3.69 for 15 oz. box, six-count snack bars cost $3.19 for all three flavors, two flavors of 48 oz. juice SKUs priced at $2.99. Additional promotions of test launch, begun late June, include Web site, toll-free info line, coupons, health professional outreach. Products will carry FDA-approved health claim for oat fiber and heart health (1"The Tan Sheet" July 9, In Brief)

You may also be interested in...



Sterol/Stanol Warning For Children, Pregnant Women Unsupported – Altus

Existing safety data do not justify restricting the phytosterol intake of infants, children or pregnant/ lactating women, Altus Food Company tells FDA

Forbes Medi-Tech

Phytrol functional food products slated for late July test launch in two U.S. cities by Novartis/Quaker Oats joint venture Altus, Forbes reports July 3. Line of phytosterol-containing drinks, cereals and bars will be sold under Quaker Take Heart brand and be competitively priced with other specialty products. Revenue from Phytrol sales for fiscal Q3 (ended April 30) totaled approximately $232,000 (CAN$351,000), although majority of sales in preparation for test market launch were completed by February 2001, Forbes says. Phytrol sales for first nine months totaled about $1.3 mil. Vancouver-based firm reports Q3 net loss of roughly $2.2 mil., compared to $1.9 mil. loss in year-ago quarter. Company aims to launch CardioRex dietary supplement for cholesterol control in first half of 2002

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel